Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

This study is ongoing, but not recruiting participants.

First Received: December 16, 2005 Last Updated: July 16, 2008 History of Changes

Sponsored by:	Allergopharma Joachim Ganzer KG
Information provided by:	Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier:	NCT00266526

Purpose

Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV

Condition	Intervention	Phase
Birch Pollen Allergy	Biological: Recombinant birch pollen	Phase II

MedlinePlus related topics: Allergy Hay Fever

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-Adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen

Further study details as provided by Allergopharma Joachim Ganzer KG:

Study Start Date:	July 2003
Estimated Study Completion Date:	July 2004

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00266526

Locations

Germany
Allergopharma Joachim Ganzer KG
Reinbek, Germany, 21465

Sponsors and Collaborators

Allergopharma Joachim Ganzer KG

Investigators

Principal Investigator:

Annemie Narkus, M.D.

unaffiliated

More Information

Additional Information:

Leader in specific allergy research and therapy This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	Al0303rB
Study First Received:	December 16, 2005
Last Updated:	July 16, 2008
ClinicalTrials.gov Identifier:	NCT00266526 History of Changes
Health Authority:	Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma Joachim Ganzer KG:

Allergy
Birch pollen
Recombinant

Study placed in the following topic categories:

Hypersensitivity
Otorhinolaryngologic Diseases
Respiratory Tract Diseases
Rhinitis, Allergic, Seasonal

Hypersensitivity, Immediate
Rhinitis
Aluminum Hydroxide
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Hypersensitivity
Otorhinolaryngologic Diseases
Immune System Diseases
Respiratory Tract Diseases
Rhinitis, Allergic, Seasonal

Hypersensitivity, Immediate
Rhinitis
Nose Diseases
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on May 07, 2009